Inhibitors of PDE4: A review of recent patent literature

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 7, 2005, Pages 773-787

  Odingo, Joshua O ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Asthma; cAMP; Chronic obstructive pulmonary disease (COPD); Phosphodiesterase 4 (PDE4); TNF

Indexed keywords

4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; ANTIHISTAMINIC AGENT; BAY 19 8004; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CC 10004; CILOMILAST; CORTICOSTEROID; CP 671305; ERYTHROMYCIN; HT 0712; IC 485; LOTEPREDNOL ETABONATE; MEM 1414; MESOPRAM; MONTELUKAST; MUSCARINIC M3 RECEPTOR ANTAGONIST; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OGLEMILAST; ONO 6126; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SALBUTAMOL; TETOMILAST; TOFIMILAST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; ATOPIC DERMATITIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE MODEL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HUMAN; MEDICAL LITERATURE; MEMORY DISORDER; META ANALYSIS; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NONHUMAN; PATENT; RAT; REGISTRATION; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNITED STATES;

EID: 22744435196     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.7.773     Document Type: Review

References (55)

1. NICHOLSON CD, CHALLISS RAJ, SHAHID M: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. (1991) 12:19-27.
2. NICHOLSON CD, SHAHID M: Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulm. Pharmacol. (1994) 7:147.
3. CONTI M, JIN LS: The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. (1999) 63:1-38.
4. TORPHY TJ: Phosphodiesterase isozymes: molecular targets for novel anti-asthma agents. Am. J. Respir. Crit. Care Med. (1998) 157:351-370.
5. HOROWSKI R, SASTRE-Y-HERNANDEZ M. Curr. Ther. Res. (1998) 38:23-29.
6. SOUNESS JE, RAO S: A proposal for pharmacologically distinct conformers of PDE4. Cell. signal. (1997) 9:227-236.
7. LALIBERTE F, HAN Y, GOVINDARAJAN A et al.: Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry (2000) 39(21):6449-6458.
8. LIU S, LALIBERTE F, BOBECHKO B et al.: Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry (2001) 40(34):10179-10186.
9. GLAXOSMITHKLINE, INC.: GlaxoSmithKline receives FDA approvable letter for Ariflo (cilomilast) tablets 15 mg. Press release (27 October 2003).
10. CHRISTENSEN SB, GUIDER A, FORSTER CJ et al.: 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J. Med. Chem. (1998) 41:821-835.
11. REISNER T et al.: Cilomilast is efficacious in chronic obstructive pulmonary disease (COPD). Eur. Respir. J. (2003) 22(Suppl.5): Abst. P530.
12. FERGUSON G, FISCHER TL, MORIS A et al.: Cardiovascular safety of cilomilast in patients with chronic obstructive pulmonary disease. Chest (2003) 124(Suppl.4):171S.
13. RABE F, O'DONNELL D, MUIR F et al.: Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD. Eur. Respir. J. (2004) 24(Suppl.48): Abst. 267.
14. BETHKE TD, BATEMAN ED, VAN NOORD JA et al.: Long-term safety of roflumilast in the treatment of chronic obstructive pulmonary disease. Chest (2004) 126(Suppl.4):805S.
15. HUENNEMEYER A, ZECK K, BETHKE TD et al.: Oral, once-daily roflumilast and its active N-oxide metabolite exhibit dose proportional pharmacokinetics between 250 μg and 500 μg. Chest (2004) 126(Suppl.4):804S.
16. MANEGOLD A, HAUNS B, HUENNEMEYER A et al.: Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide is not influenced by erythromycin. Eur. Respir. J. (2004) 24(Suppl.48): Abst. P867
17. HAUNS B, HUENNEMEYER A, KILIAN U et al.: Lack of pharmacokinetic interaction of roflumilast and its oxide metabolite, roflumilast N-oxide, with budesonide or salbutamol. 4th World Asthma Meet (16 Feb- 19 Feb 2004) Bangkok: Abst. P229-P230.
18. BARDIN PG, VAN SCHALKWYK EM, VAN HEERDEN K et al.: Inhibition of late asthmatic reaction in allergic asthma by roflumilast, a selective phosphodiesterase 4 inhibitor. 4th World Asthma Meet (16-19 Feb 2004) Bangkok: Abst. 0-228.
19. BATEMAN D, IZQUIERDO L, VETTER N et al.: Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma. Eur. Respir. J. (2003) 22(Suppl.45): Abst. 1393
20. WOLLIN L, BARSIG J, MARX D et al.: Eur. Respir. J. (2003) 22(Suppl.45): Abst. P739.
21. TIMMER W, LECLERC V, BIRRAUX G et al.: The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J. Clin. Pharmacol. (2002) 42(3):297.
22. CHIHIRO M, NAGAMOTO H, TAKEMURA I et al.: Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships. J. Med. Chem. (1995) 38:353-358.
23. ONAGAWA T, NAGAMOTO H, MAEDA T et al.: J. Mol. Cell Cardio. (1998) 30: Abst. 37.
24. NAGAMOTO H, MAEDA T, SUEYOSHI H et al.: OPC-6535 inhibits human and porcine monocyte tumor necrosis factor-α production in vitro and in vivo. Gastroenterology (2004) 126(4, Suppl.2): Abst. W1090.
25. HANAUER SB, MINER PB, KESHAVARZIAN A et al.: Randomized, double-blind, placebo-controlled, parallel arm, safety and efficacy trial of once-daily, oral OPC-6535 in the treatment of active ulcerative colitis (UC). Gastroenterology (2004) 126(4, Suppl.2): Abst. 814.
26. KALGUTKAR AS, CHOO E, TAYLOR TJ, MARFAT A: Disposition of CP-671,305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica (2004) 34(8):755-770.
27. LOHER F, SCHMALL K, FREYTAG P et al.: The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J. Pharmacol. Exp. Ther. (2003) 305(2):549-556.
28. MARX D, POPPE H, KUESTERS S, HEER S, SZELENYI I: The pharmacological activity of AWD 12-281, a potent phosphodiesterase 4 (PDE4) inhibitor for the treatment of allergic rhinitis and asthma. Pneumologie (1999) 53(9):443.
29. KUSS H, HOEFGEN N, JOHANSSEN S et al.: In vivo efficacy in airway disease models of N-(3,5-dichloropyridin-4-yl)-[1-(4 -fluorobenzyl-5- hydroxy-indole-3-yl]-glyoxidic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J. Pharmacol. Exp. Ther. (2003) 307(1):373.
30. KUSS H, HOEFGEN N, RUNDFELDT C et al.: AWD 12-281, a new PDE4-inhibitor, suppresses allergen-induced 'early phase' bronchoconstriction in sensitized guinea pigs. Eur. Respir. J. (2003) 22(Suppl.45): Abst. 107S.
31. ICOS CORP.: Phase II study of IC485 in COPD does not meet primary efficacy endpoint; ongoing PDE4 program to focus on preclinical candidates. Press release (23 March 2005).
32. FURUIE H, NAKAGAWA S, KAWASHIMA M et al.: Suppressive effect of novel phosphodiesterase 4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects. Eur. Respir. J. (2003) 22(Suppl.45): Abst. 2557.
33. TAKEDA H et al.: Pharmacological profile of Ono-6126, a novel phosphodiesterase 4 (PDE4) inhibitor. 98th Int. Conf. Am. Thorac. Soc. Atlanta, USA (17 May - 22 May 2002): Abst. H41.
34. MEMORY PHARM.: Memory Pharmaceuticals provides update on PDE4 collaboration with Roche. Press release (15 April 2005).
35. HELICON THERAPEUTICS, INC.: Helicon Therapeutic, Inc. commences Phase I human testing of the company's lead drug candidate. News Release (10 December 2004).
36. BOURTCHOULADZE R, LIDGE R, CATAPANO R et al.: A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl. Acad. Sci. USA (2003) 100(18):10518.
37. VAKKALANKA SK, BALASUBRAMANIAM G, GHARAT LA et al.: The pharmacological and safety profile of a novel selective phosphodiesterase-4 (PDE4) inhibitor: GRC-3886. Eur. Respir. J. (2004) 24(Suppl.48): Abst. P1391
38. UNDERWOOD DC, KOTZER CJ, BOCHNOWICZ S et al.: Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophilia influx in guinea pigs. J. Pharmacol. Exp. Ther. (1994) 270(1):250-259.
39. COLUCCI WS, WRIGHT RF, BRAUNWALD E: New positive inotropic agents in the treatment of congestive heart failure. Mechanism of action and recent clinical developments. N. Engl. J. Med. (1986) 314(6):349-358.
40. TRIFILIEFF A, WYSS D, WALKER C et al.: Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[ 1,2,5]-oxadiazol-5-yl-[1,7]-naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative with anti-inflammatory activities. J. Pharmacol. Exp. Ther. (2002) 301(1):241-248.
41. OCHIAI H, OHTAMI T, ISHIDA A et al.: Highly potent PDE4 inhibitors with therapeutic potential. Bioorg. Med. Chem. (2004) 12(17):4645-4665.
42. ZHANG HT, CRISSMAN AM, DORAIRAJ NR et al.: Inhibition of cyclic phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology (2000) 23:198-204.
43. JIN SL, CONTI M: Induction of cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl. Acad. Sci. USA (2002) 99(11):7628-7633.
44. MEHATS C, JIN SL, WAHLSTROM J et al.: PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB (2003) 17(13):1831-1841.
45. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. (2002) 110(7):1045-1052.
46. XU RX, HASSELL AM, VANDERWALL D et al.: Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (2000) 288:1822-1825.
47. HUAI Q, COLICELLI J, KE H: The crystal structure of AMP-bound PDE.4D suggests a mechanism for phosphodiesterase catalysis. Biochemistry (2003) 42(45):13220-13226.
48. LEE ME, MARKOWITZ J, LEE JO et al.: Crystal structure of phosphodiesterase 4D and inhibitor complex. FEBS Lett. (2002) 530:53-58.
49. HUAI Q, WANG H, KIM H-Y et al.: Three-dimensional structures of PDE4D in complex with rolipram and implications on inhibitor selectivity. Structure (2003) 11(7):865-873.
50. XU RX, ROCQUE WJ, LAMBERT MH et al.: Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J. Mol. Biol. (2004) 337(2):355-365
51. CARD GL, ENGLAND BP, SUZUKI Y et al.: Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (2004) 12(12):2233-2247
52. CARD G, BLASDEL L, ENGLAND BP et al.: A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol. (2005) 23(2):201-207.
53. PLEXXIKON, INC.: Robust discovery platform accelerates developments of selective inhibitors for respiratory disease. Press release (13 November 2003).
54. ZHANG KY, CARD GL, SUZUKI Y et al.: A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell (2004) 15:279-286.
55. MANALLACK DT, HUGHES RA, THOMPSON PE: The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J. Med. Chem. (2005) 48(10):3449-3462.